Article
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.
Leukemia & lymphoma - 1 Aug 2024
Bewersdorf Jan Philipp, Patel Kishan K, Shallis Rory M, Podoltsev Nikolai A, Kewan Tariq, Stempel Jessica, Mendez Lourdes, Stahl Maximilian, Stein Eytan M, Huntington Scott F, Goshua George, Zeidan Amer M
Abstract excerpt
The FLT3 inhibitor quizartinib has been shown to improve overall survival when added to intensive induction chemotherapy ("7 + 3") in patients 18-75 years old with newly diagnosed AML harboring a FLT3-ITD mutation. However, the health economic implications of this approval are unknown. We evaluated the cost-effectiveness of quizartinib using a partitioned survival analysis model. One-way and probabilistic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.